ClinicalTrials.gg
CompletedNCT06407583ProMIO2Updated May 9, 2024

ProMIO2.0; A Powerful Lifestyle Intervention for Older Adults From Ethnic Minorities

An interventional study of ProMIO2.0 program in Sarcopenia, Diabetes and Overweight, sponsored by Amsterdam University of Applied Sciences. Completed at 1 site in Netherlands. Open to participants aged 55 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-05-09.

Sponsored by Amsterdam University of Applied Sciences · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Registered 1 year 1 month after the study started (first participant enrolled May 2022, registered Jul 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
76
Allocation
Randomized
Ages
55 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 32 studies in Sarcopenia with a site in Netherlands — 1 open to participants now, 2 under way, none of them phase 3. Sarcopenia · Netherlands.

Enrollment
7th of 29
76 · median 45
Started
2022
with 4 others
No phase
23 of 32
1 open now
Registered
29th of 32
by date
Lead sponsor
1 of 32
Amsterdam University of Applied Sciences

Among the 32 studies in Sarcopenia with a site in Netherlands, this one is the 7th largest by enrollment of the 29 interventional ones that give a count, is one of 5 that started in 2022, is one of 23 with no phase, and was the 29th registered.

Sarcopenia

1,334 studies on the registry are indexed under Sarcopenia; 418 are open to participants now.

Browse Sarcopenia studies →

Open to participants now

1 of the 32 studies in Sarcopenia with a site in Netherlands is open now. Recruiting first, the newest first:

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 246 Sarcopenia studies recruiting now, 155 (63%) set no upper age limit and 32 (13%) stop at 75 or younger; 9 take children under 18; 62 take healthy volunteers.

This study: 55 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Sarcopenia with a site in Netherlands, or all of them as a file.
02

Study summary

Older adults from ethnic minorities show on average a worse disease risk profile compared to the majority populations. An important risk factor to develop chronic diseases is the loss of muscle mass and functioning, also known as sarcopenia. Several randomized controlled trials (RCTs) showed that the combination of adequate protein intake and physical exercise is most effective to prevent the loss of muscle mass, strength and functioning in older adults. However, until shortly, no intervention that included protein and exercise was available that accounted for the special socio-cultural needs of ethnic minority populations. Therefore the Amsterdam University of Applied Sciences (AUAS) and ProMIO project group developed a cultural sensitive lifestyle intervention with protein and exercise carried out by dieticians and physical therapists to provide a tailored treatment for older adults from ethnic minorities. This project aims to evaluate the effectiveness of this new intervention on protein intake, physical activity behavior, muscle mass, muscle strength, function and quality of life. The cost-effectiveness of this new intervention will also be evaluated.

Read the detailed description

Primary Objective: To investigate the effectiveness of the ProMIO lifestyle intervention (targeting protein intake and exercise behavior) on physical functioning, in older adults from ethnic minorities (Surinamese).

The intervention will be a lifestyle intervention targeted at changing health behaviors in older adults from ethnic minorities in the Netherlands. Methods will be used that target specific behavioral determinants in order to optimize both exercise and dietary behavior. We aim to reach the following behavioral outcomes:

  • 1.2g/kg BW/day (\~25 - 30 grams of protein per meal (4x/day))
  • Reaching the WHO physical activity guidelines for older adults:

    • At least 150-300 minutes/week moderate-intensity aerobic physical activity (such as walking)
    • 2x/week strength, balance and functional exercises

Based on previous research it is expected that by optimizing these health behaviors, muscle mass, muscle strength, and physical functioning will improve.

Secondary Objective(s):

  • To investigate the effectiveness of the ProMIO lifestyle intervention (targeting protein intake and exercise behavior) on muscle mass and muscle strength, in older adults from ethnic minorities
  • To investigate the effectiveness of the ProMIO lifestyle intervention on protein intake and physical activity behavior in older adults from ethnic minorities
  • To investigate the cost-effectiveness of the ProMIO lifestyle intervention in comparison to an health education intervention.

The (cost-)effectiveness of the ProMIO intervention will be investigated using a single blind randomized controlled trial (RCT) with two parallel arms.

First, potential participants will be recruited and screened for eligibility. Secondly, participants will be randomly assigned to one of the two groups; the intervention group or the control group.

The full study will comprise a 6-month intervention, divided in two phases, and consisting of a multicomponent exercise training (MCE) program provided by physical therapists and a protein intervention provided by dieticians. Each participant will be supervised and monitored by a physical therapist and a dietician, who are providing regular consulting sessions.

Exercise activities, like group exercise training, will be provided by certified trainers and health education will be provided by AUAS graduate students with a background in nutrition and/or physical exercise. Certified trainers and graduate students are supervised and guided by the physical therapist and dietician. The intensity of the professional support during the intervention will be highest in the first phase and taper off during the second phase. Participants are expected to adopt most of the desired behavioral activities in daily living without professional help. Data will be collected at baseline (T1) and after 3 (T2), and 6 (T3) months.

Outcome measures are a combination between quantitative and qualitative outcome.

03

Conditions studied

  • Sarcopenia
  • Diabetes
  • Overweight
  • Ethnic Minorities
  • Musculoskeletal Diseases

Keywords

  • Lifestyle intervention
  • Protein
  • Multicomponent exercise
  • Older adults
  • Ethnic minorities
04

Who can participate

Ages eligible
55 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Born in Surinam (or at least one of the parents was born there)
  • Aged ≥55 years
  • Physical ability and willingness to execute an MCE program
  • Ability and willingness to comply with the study protocol
  • Written
  • Consent of the study physician

Exclusion criteria

Exclusion Criteria:

  • Aged \<55 years
  • Diagnosed with renal insufficiency (\<30, GP approved)
  • Suffering from physical disabilities causing the inability to perform the main exercises (walking aids or mild visual impairment are not an exclusion criteria)
  • Diagnosed unstable coronary heart disease (CHD), decompensated heart failure, or uncontrolled arrhythmias
  • End stage (COPD) GOLD >3
  • Phase IV cancer
  • Diagnosed degenerative neurocognitive disorders
  • Active (para-)medical treatment interfering with this intervention
  • Current enrolment in a fixed rehabilitation program or other intervention studies
  • Palliative treatment or a of ≤3 months
  • A trip >2 weeks planned in first three months of study or >2 months during the rest of the intervention period
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
76 participants (actual)

Study arms

  • No intervention
    Control group

    Participants receiving regular care in the 6 months period. They receive a brief education session at start about exercise and protein.

  • Experimental
    ProMIO2.0 intervention group

    Participants receiving regular care and our newly developed lifestyle intervention for 6 months period. The intervention is culture specific and contains of: * Dietetic care focused on protein intake (protein counselling) * Multicomponent exercise (physical therapy); a combination between group sessions and home-based exercise The first 3 months are intensive phase, second 3 months guidance gradually decreases.

    Behavioral: ProMIO2.0 program

Interventions

  • BehavioralProMIO2.0 program

    ProMIO2.0 is a lifestyle intervention carried out by physiotherapy and dietetics. They guide and encourage the participants to achieve the following behavioral goals: * moderate/intensive exercise (e.g. walking) for 150-300 minutes per week * Muscle-strengthening exercises 2x a week * Supplemented with balance and flexibility exercises * 1.2 grams of protein per kilogram of body weight per day (\~25-30 grams of protein per meal, 4x/day) The combination of consultations, information sessions and on-site training at the physiotherapist should ensure that participants acquire the necessary knowledge, awareness and skills to adopt the health behavior in daily life. Materials such as posters, pedometers and videos are used for support. The intervention is divided into 2 phases, which indicate the degree of professional guidance: 1. intensive guidance (month 0 - 3) 2. average guidance (months 4 - 6)

06

What researchers measure

Primary outcomes

  1. Physical functioning

    change in meters from baseline to 3 months by 6 Minute Walk Test

    Time frame: baseline, 3 months

  2. Physical functioning

    change in meters from baseline to 6 months by 6 Minute Walk Test

    Time frame: baseline, 6 months

Secondary outcomes

  1. 30-sec Chair Stand Test

    (frequency) change from baseline to 3 or 6 months

    Time frame: baseline, 3 months, 6 months

  2. Balance (Single Leg Stand Test)

    (seconds) - change from baseline to 3 or 6 months

    Time frame: baseline, 3 months, 6 months

  3. Strenght (1RM with Microfet)

    (kg) change from baseline to 3 or 6 months

    Time frame: baseline, 3 months, 6 months

  4. Strenght with Hand Grip Strenght

    (kg) change from baseline to 3 or 6 months

    Time frame: baseline, 3 months, 6 months

  5. Body composition Lenght

    (meters) change from baseline to 3 or 6 months

    Time frame: baseline, 3 months, 6 months

  6. Body composition Weight

    (kg) change from baseline to 3 or 6 months

    Time frame: baseline, 3 months, 6 months

  7. Body composition BMI

    (kg/m2) change from baseline to 3 or 6 months

    Time frame: baseline, 3 months, 6 months

  8. Body composition 2D muscle echo

    (cm2) change from baseline to 3 or 6 months

    Time frame: baseline, 3 months, 6 months

  9. Behavioral outcome - Dietary intake (48h recall)

    macronutrient and micronutrient change from baseline to 3 or 6 months

    Time frame: baseline, 3 months, 6 months

  10. Behavioral outcome - Physical Activity

    (PAMscore) - change from baseline to 3 or 6 months

    Time frame: baseline, 3 months, 6 months

  11. Quality of Life (QoL)

    (score) change from baseline to 3 or 6 months

    Time frame: baseline, 3 months, 6 months

  12. Sarcopenia screening (SarQoL)

    (score) change from baseline to 3 or 6 months

    Time frame: baseline, 3 months, 6 months

  13. Frailty

    (score) change from baseline to 3 or 6 months

    Time frame: baseline, 3 months, 6 months

  14. Activities of Daily Living (ADL) Katz

    (score) change from baseline to 3 or 6 months

    Time frame: baseline, 3 months, 6 months

  15. Pain (NRS)

    (NRS) change from baseline to 3 or 6 months

    Time frame: baseline, 3 months, 6 months

  16. Sleep (NRS)

    (NRS) change from baseline to 3 or 6 months

    Time frame: baseline, 3 months, 6 months

  17. Risk of Falls (NRS)

    (NRS) change from baseline to 3 or 6 months

    Time frame: baseline, 3 months, 6 months

  18. Efficacy Scale International (sFES-I)

    (score) change from baseline to 3 or 6 months

    Time frame: baseline, 3 months, 6 months

  19. symptoms of depression (CES-D)

    (score) change from baseline to 3 or 6 months

    Time frame: baseline, 3 months, 6 months

  20. Cost effectiveness - Productivity Cost Questionnaire (PCQ)

    (score) change from baseline to 6 months

    Time frame: baseline, 6 months

  21. Cost effectiveness - Cost of Quality (MCQ)

    (score) change from baseline to 6 months

    Time frame: baseline, 6 months

  22. Process evaluation

    Process evaluation questionnaire and focus group sessions

    Time frame: 6 months

  23. Social democrafic characteristics

    e.g. age (years), gender (f/m), highest education level

    Time frame: screening, baseline

  24. Medical history

    all medical events and diseases reported

    Time frame: screening

  25. Medication use

    all medication reported at start and during the trial

    Time frame: screening and during study

  26. Adverse events

    all adverse events reported during the intervention study

    Time frame: During study

  27. Adherence to the intervention

    Specified for exercise routine and protein intake; a % of attendance and minimal 1.2 g/kgBW/day protein intake

    Time frame: During study

07

Study locations

1 site
  • Amsterdam University of Applied Sciences, Center of Expertise Urban Vitality
    Amsterdam, N-H 1067SM, Netherlands
08

References and documents

Individual participant data

Plan to share: Yes — Restricted on Figshare following our OpenScience regulations

Supporting information: Study protocol, Informed consent form, Clinical study report

Time frame: After study completion

Access criteria: Restricted untill publication.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2022 to primary completion in Jun 2023, 12 months.

Of 497 non-industry interventional studies with no phase under Sarcopenia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 34. This study's 12 months is below that.

Counting every sponsor, half of 509 studies reached it within 18 months; a quarter within 8 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 6, 2023
First posted
May 9, 2024
StartActual
May 24, 2022
Primary completionActual
Jun 8, 2023
CompletionActual
Jun 8, 2023
Last update
May 9, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06407583
Lead sponsor
Amsterdam University of Applied Sciences
Responsible party
Sponsor
First posted
May 9, 2024
Start date
May 24, 2022
Primary completion
Jun 8, 2023
Completion
Jun 8, 2023
Last update
May 9, 2024

Study contacts

Peter Weijs, Prof Dr Ir
principal investigator · Amsterdam University of Applied Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion